Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.76 USD | -2.76% | -6.88% | +38.58% |
21/05 | HC Wainwright Adjusts Inhibikase Therapeutics Price Target to $23 From $27, Maintains Buy Rating | MT |
16/05 | Transcript : Inhibikase Therapeutics, Inc., Q1 2024 Earnings Call, May 16, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.58% | 1.3Cr | |
+54.05% | 6.39TCr | |
-2.02% | 4.18TCr | |
+40.01% | 4.05TCr | |
-10.22% | 2.72TCr | |
+13.42% | 2.65TCr | |
-21.60% | 1.87TCr | |
+2.89% | 1.27TCr | |
+22.40% | 1.21TCr | |
+27.49% | 1.21TCr |
- Stock Market
- Equities
- IKT Stock
- News Inhibikase Therapeutics, Inc.
- Transcript : Inhibikase Therapeutics, Inc., Q2 2023 Earnings Call, Aug 15, 2023